Document Detail


Recovery of ovarian function and pregnancy in a patient with AML after myeloablative busulphan-based conditioning regimen.
MedLine Citation:
PMID:  21423042     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report a rare case of ovarian function recovery and pregnancy after hormone-replacement therapy (HRT) in the acute myeloblastic leukemia (AML) patient in third complete remission received hematopoietic stem cell transplantation (HSCT) with busulphan-based conditioning regimen. Successful engraftment of the donor cells and full donor's chimerism was achieved without the signs of leukemia. One year after HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism. After 12 months of HRT the recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a nonsevere vaginal bleeding occurred and the ultrasound examination showed a nondeveloping pregnancy. Genetic examination of the abortion material showed a full triploid genotype (69 XXX). To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high-dose chemotherapy and busulphan-based myeloablative conditioning for HSCT.
Authors:
Dmitry N Balashov; Ludmila I Papusha; Tatiana A Nazarenko; Pavel E Trakhtman; Nino A Revishvili; Alexei A Maschan; Marina I Persiantseva; Anna V Andriutsa; Elena V Skorobogatova; Yulia V Skvortsova; Alexander G Rumiantsev
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  33     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-25     Completed Date:  2011-06-30     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e154-5     Citation Subset:  IM    
Affiliation:
Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. bala8@yandex.ru
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antineoplastic Agents / administration & dosage,  adverse effects
Busulfan / administration & dosage*,  adverse effects
Child
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation*
Humans
Hypogonadism / drug therapy
Leukemia, Myeloid, Acute / drug therapy*
Myeloablative Agonists / administration & dosage,  adverse effects
Ovary / physiology*
Pregnancy
Pregnancy Outcome
Recovery of Function*
Transplantation Conditioning / adverse effects,  methods*
Young Adult
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Myeloablative Agonists; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ocular Hypotensive Effect of Tafluprost in Latanoprost Low-responder Cynomolgus Monkeys.
Next Document:  Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good ...